From diagnosis to treatment: the relevance of atomoxetine in the management of ADHD

Abstract

Attention Deficit Hyperactivity Disorder (ADHD) is a neuropsychiatric condition that affects children, adolescents, and adults, impairing academic, professional, and social performance. Treatment includes psychotherapeutic and pharmacological approaches, with stimulants being the first choice. However, not all patients respond well to these medications, requiring alternative therapies. Atomoxetine, a selective norepinephrine reuptake inhibitor, has proven to be an effective option, especially for individuals with contraindications to stimulants or comorbid psychiatric disorders. Its mechanism of action improves attention, impulse control, and hyperactivity without the risk of abuse or dependence. Studies indicate that atomoxetine has a favorable safety profile, despite adverse effects such as gastrointestinal disturbances and fatigue. In conclusion, atomoxetine is a valuable alternative in ADHD management, requiring proper monitoring to optimize its benefits and minimize risks. Further research is needed to evaluate its long-term efficacy and refine its clinical use.